S4-E34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

Send us Fan MailThis month, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from June's two major conferences: the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. In doing so, the Big Band of Surfers (Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green) are joined by Mazen Noureddin for a fascinating conversation which covers compelling data and ideas emerging from the drug development space.This episode starts with a welcome (and happy birthday) to Roger as he belatedly joins the discussion. From here Mazen discusses some of the implications of the anticipated upcoming approval for resmetirom and what that will mean for treatment, drug development and noninvasive tests. Stephen nexts dives into the phase 2b pemvidutide trial in greater detail. In response, Jörn notes that the weight loss is not what you might have expected from a GLP-1 and asks whether this has to be a function of GLP-1 to glucagon ratio. Stephen notes that there is a relatively high level of glucagon to GLP-1 in pemvidutide that might translate not only into greater antifibrotic activity, but also possibly a lower level of side effects relative to a combination agent with a lower level of glucagon compared to GLP-1.  Each conversation covers a lot of ground on drug development, analysis of trial results, and the upcoming increases in importance of omics and artificial intelligence. If you have questions or comments around the EASL Congress or ADA meetings, or the themes and data discussed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected] Safe and Surf On